Turner White CommunicationsAbout TWCSubscribeContact TWCHomeSearch
Hospital PhysicianJCOMSMPBRMsCart
Current Contents
Where We Are Indexed
Past Issue Archives
Clinical Communication
CME
Outcomes
Research
In Review
Editorial Board
Information for Authors
Author Form

Reprints, Permissions, & Copyright
Site Map
 
JCOM
BACK ISSUE articles are $15 each.
 
International credit cards NOT accepted.



JCOM Paid Subscribers
LOG IN
user name:
password:
 
Forgot password?

JCOM Abstract


J Clin Outcomes Manage 
2005 Jan;12(1):25-31
Perioperative anticoagulation for patients with mechanical heart valves: a model comparing unfractionated and low-molecular-weight heparin
Garcia DA, Libby EN, Rich JS

Abstract Objective: To assess the cost-effectiveness of perioperative anticoagulation with intravenous unfractionated heparin (UFH) in patients with mechanical heart valves. Design: Decision analysis using a Markov model. Setting and participants: A hypothetical cohort of men and women aged 55 years with a St. Jude mitral valve and a history of atrial fibrillation receiving perioperative antithrombotic agents. Inputs: Rate of major thromboembolic events (stroke, valve thrombosis, peripheral embolus) in patients with a mechanical mitral valve who are anticoagulated with warfarin or heparin (2.3 events per 100 patient-years) or with low-molecular-weight heparin (LMWH) (3.4 events per 100 patient-years); risk of death or permanent sequelae following a thromboembolic event; and costs from the third-party payer perspective of the thromboprophylaxis strategies and the long-term costs associated with thromboembolic complications. Measurements: Incremental cost-effectiveness ratios and potential thromboembolic events averted. Results: Assuming a relative risk increase of 50% in valve-related thromboembolic events in patients treated with LMWH, the incremental cost-effectiveness ratio for intravenous UFH is more than $3,000,000 per quality-adjusted life-year. Relative to the protection provided by LMWH, an additional 4167 patients would have to be hospitalized for intravenous UFH to prevent 1 thromboembolic event. Conclusion: Bridging all patients with mechanical heart valves with intravenous UFH is prohibitively expensive. Consensus panels charged with establishing guidelines for the management of this increasingly common clinical problem must weigh patient safety and medicolegal concerns along with the potential economic impact of their recommendations.

Article

Search the Turner White index to find abstracts of articles published in JCOM.





New issues are posted one month following publication of the printed journal.



View past issue archives:    2013    2012    2011    2010    2009    2008    2007
   2006    2005    2004    2003     2002     2001     2000     1999



Hospital Physician     JCOM     Seminars in Medical Practice
Hospital Physician Board Review Manuals
About TWC    Subscribe    Contact TWC    Home    Search   Site Map

Copyright © 2014, Turner White Communications
Updated 1/20/14 • jdw